The Effect of Clozapine and Novel Glutamate Modulator JNJ-46356479 on Nitrosative Stress in a Postnatal Murine Ketamine Model of Schizophrenia.
clozapine
glutamate metabotropic modulator
ketamine
nitrosative stress
schizophrenia
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
09
11
2022
revised:
26
12
2022
accepted:
26
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Schizophrenia (SZ) is a heterogeneous mental disorder, affecting ~1% of the worldwide population. One of the main pathophysiological theories of SZ is the imbalance of excitatory glutamatergic pyramidal neurons and inhibitory GABAergic interneurons, involving N-methyl-D-aspartate receptors (NMDAr). This may lead to local glutamate storms coupled with excessive dendritic pruning and subsequent cellular stress, including nitrosative stress, during a critical period of neurodevelopment, such as adolescence. Nitrosative stress is mediated by nitric oxide (NO), which is released by NO synthases (NOS) and has emerged as a key signaling molecule implicated in SZ. Regarding glutamatergic models of SZ, the administration of NMDAr antagonists has been found to increase NOS levels in the prefrontal cortex (PFC) and ventral hippocampus (HPC). We hypothesized that suboptimal NOS function in adolescence could be a target for early treatments, including clozapine (CLZ) and the novel metabotropic glutamate receptor modulator JNJ-46356479 (JNJ). We analyzed the protein levels of NOS isoforms in adult PFC and HPC of a postnatal ketamine induced murine model of SZ receiving CLZ or JNJ during adolescence by western blot. Endothelial NOS and neuronal NOS increased under ketamine administration in PFC and decreased in CLZ or JNJ treatments. The same trends were found in the HPC in neuronal NOS. In contrast, inducible NOS was increased under JNJ treatment with respect to ketamine induction in the HPC, and the same trends were found in the PFC. Taken together, our findings suggest a misbalance of the NOS system following NMDAr antagonist administration, which was then modulated under early CLZ and JNJ treatments.
Identifiants
pubmed: 36674542
pii: ijms24021022
doi: 10.3390/ijms24021022
pmc: PMC9866372
pii:
doi:
Substances chimiques
Clozapine
J60AR2IKIC
Ketamine
690G0D6V8H
Glutamic Acid
3KX376GY7L
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI18/01005
Organisme : Instituto de Salud Carlos III
ID : PI21/0552
Références
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Transl Psychiatry. 2017 Jul 18;7(7):e1171
pubmed: 28934193
Eur J Pharmacol. 2015 Nov 5;766:106-13
pubmed: 26435027
Behav Brain Res. 2015 Apr 1;282:165-75
pubmed: 25591475
Neuropsychobiology. 2005;52(3):111-7
pubmed: 16110244
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:66-76
pubmed: 25724760
J Med Chem. 2016 Sep 22;59(18):8495-507
pubmed: 27579727
Biol Psychiatry. 2020 Aug 15;88(4):326-336
pubmed: 32560962
Prog Neurobiol. 2001 May;64(1):51-68
pubmed: 11250062
PLoS One. 2010 Jun 29;5(6):e11374
pubmed: 20613880
Neuroscience. 2013 Oct 22;251:90-107
pubmed: 22546337
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1523-8
pubmed: 16806626
Schizophr Bull. 2020 Jul 8;46(4):1019-1025
pubmed: 32083289
J Neurosci Res. 2008 Mar;86(4):785-96
pubmed: 17918747
Schizophr Res. 2016 Jan;170(1):226-31
pubmed: 26706197
J Vet Res. 2020 Sep 16;64(3):445-453
pubmed: 32984637
Psychol Med. 2022 Jun 09;:1-14
pubmed: 35678455
Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2811-4
pubmed: 1707173
Behav Brain Res. 2021 Jul 9;409:113304
pubmed: 33865887
Neuropharmacology. 2002 Mar;42(3):414-20
pubmed: 11897119
Schizophr Bull. 2004;30(4):923-34
pubmed: 15954198
Psychoneuroendocrinology. 2020 Jan;111:104473
pubmed: 31655452
Schizophr Bull. 2016 Mar;42(2):279-87
pubmed: 26316594
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7797-801
pubmed: 1715581
Schizophr Res. 2005 Oct 1;78(1):69-86
pubmed: 16005189
Transl Psychiatry. 2021 May 6;11(1):271
pubmed: 33958577
J Affect Disord. 2018 Jul;234:148-155
pubmed: 29529547
Curr Alzheimer Res. 2016;13(2):185-97
pubmed: 26679860
Schizophr Res. 2010 Aug;121(1-3):172-8
pubmed: 20605417
Nat Commun. 2020 Sep 1;11(1):4388
pubmed: 32873805
Schizophr Res. 2015 Sep;167(1-3):98-107
pubmed: 25583246
J Psychiatr Res. 2020 Jul;126:8-18
pubmed: 32407891
Sleep Med Rev. 2005 Apr;9(2):101-13
pubmed: 15737789
Psychiatry Res. 2017 Jul;253:43-48
pubmed: 28346888
Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d
pubmed: 21890489
Nat Rev Neurosci. 2007 Oct;8(10):766-75
pubmed: 17882254
Front Psychiatry. 2019 Nov 21;10:835
pubmed: 31824347
Mol Brain. 2017 Apr 26;10(1):15
pubmed: 28446243
J Neural Transm (Vienna). 2009 Aug;116(8):941-52
pubmed: 19475335
Neurosci Biobehav Rev. 2015 Aug;55:612-26
pubmed: 26092265
Schizophr Res. 2020 Aug;222:23-30
pubmed: 32475621
Brain Res. 2021 Oct 1;1768:147577
pubmed: 34217728
Front Physiol. 2015 May 11;6:139
pubmed: 26029110
Arch Gen Psychiatry. 1993 Mar;50(3):224-7
pubmed: 8439244
Ren Fail. 2015 May;37(4):722-6
pubmed: 25687386
Arch Gen Psychiatry. 1993 Mar;50(3):178-87
pubmed: 7679892
CNS Neurol Disord Drug Targets. 2015;14(8):979-87
pubmed: 26350341
Pharmacol Res Perspect. 2015 Feb;3(1):e00096
pubmed: 25692015
Prog Neurobiol. 2021 Apr;199:101967
pubmed: 33271238
Neuropharmacology. 2012 Mar;62(3):1322-31
pubmed: 21315745